source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…
- US biotech M&A surges as Chinese licensing deals dominate 2026 marketLocust Walk reports that China now accounts for 58% of global licensing deal value in 2026, while the United States share has dropped to 26%. Despite the licensing shift, US biotech companies are…